Clinical trials
Renal Cell Cancer Metastatic clinical trials
Below are recruiting renal cell cancer metastatic clinical trials, each written for real people, not researchers. We’re tracking 605 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05269381RecruitingPhase 1/Phase 2
Personalized cancer vaccine with pembrolizumab for advanced solid tumors
This trial tests a personalized vaccine made from your tumor's unique markers, combined with the drug pembrolizumab, to help your immune system fight cancer. It is for people with advanced solid tumors who have already tried standard treatments.
Jacksonville, FloridaAges 16 years+ - NCT07623369RecruitingPhase 1
First-in-Human Study of HH160 for Advanced Solid Tumors
This is an early-stage trial testing a new drug called HH160 in patients with advanced cancer (solid tumors). Researchers want to find the right dose and learn how well it works and what side effects it causes.
Waratah, New South WalesAges 18–75 - NCT07123090RecruitingPhase 2
Triple Therapy for Advanced Kidney Cancer
This trial tests a combination of three drugs—sasanlimab (immunotherapy), palbociclib (targeted therapy), and axitinib (VEGF inhibitor)—for people with advanced kidney cancer who have not had prior treatment. It aims to see if this triple therapy is safe and effective.
Boston, MassachusettsAges 18 years+ - NCT07197671RecruitingPhase 1
Radiation drug for people with head and neck cancer on immunotherapy
This study tests a radioactive drug called Y-NM600 that may help treat head and neck cancer that has spread. It is given to people who are already receiving an immunotherapy drug (like Keytruda or Opdivo) and whose cancer is stable or slightly growing.
Madison, WisconsinAges 18 years+ - NCT05361720RecruitingPhase 2
Genetic test to match treatment for advanced kidney cancer
This study looks at genetic (RNA) testing of kidney cancer tissue to help choose the best drug treatment. It may help guide therapy for people with advanced or metastatic clear cell kidney cancer who are starting treatment for the first time.
Duarte, CaliforniaAges 18 years+ - NCT07636785RecruitingPhase 1/Phase 2
VMD-102 Drug Study for Advanced Cancers
This study tests a new drug called VMD-102 in patients with advanced liver cancer, melanoma, kidney cancer, lung cancer, or colon cancer that hasn't responded to standard treatments. The trial will help determine if VMD-102 is safe and effective at slowing or stopping cancer growth.
Scottsdale, ArizonaAges 18–75 - NCT05287945RecruitingPhase 1/Phase 2
Orellanine for kidney cancer patients on dialysis
This early-stage study tests orellanine to treat advanced kidney cancer that has spread (metastatic clear-cell or papillary type). It may help by shrinking or controlling cancer, and by seeing whether the treatment is safe and tolerable in people already on chronic dialysis.
Orange, CaliforniaAges 18 years+ - NCT06822543RecruitingPhase 2
A new treatment for lung cancer that has spread to the brain
This trial tests a combination of three drugs (datopotamab deruxtecan, carboplatin, and pembrolizumab) for people with a type of lung cancer called non-small cell lung cancer (NSCLC) that has spread to the brain and has not been treated before. The goal is to see if this combination can shrink tumors in the brain and elsewhere.
Fortaleza, CearáAges 18 years+ - NCT05733715RecruitingEarly Phase 1
Testing pembrolizumab plus lenvatinib before kidney cancer surgery
This trial tests whether giving pembrolizumab (an immune medicine) and lenvatinib (a targeted medicine) before surgery can shrink or better treat renal cell carcinoma. The goal is to improve surgical outcomes and help the body fight the cancer.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05706129RecruitingPhase 1/Phase 2
Testing targeted imaging and therapy for advanced solid tumors
This early-phase study tests two radioactive medicines that first help doctors see tumors and, in some parts of the study, treat them. It may help people with advanced, hard-to-remove cancers that have a specific tumor marker (CA IX).
MelbourneAges 18 years+ - NCT07187869RecruitingPhase 1
Cabozantinib plus nivolumab for kidney cancer with bone spread
This study tests whether adding a drug called cabozantinib to standard nivolumab treatment helps fight kidney cancer that has spread to bone. It aims to understand how the bone environment changes during treatment.
Houston, TexasAges 18 years+ - NCT02102165Recruiting
Study samples from metastatic triple-negative breast cancer
This study looks at tumor “clues” by using tissue and blood samples in people with metastatic breast cancer (with specific subtype). It aims to better understand what drives the cancer, which may help guide future treatments.
BrusselsAges 18 years+ - NCT07188896RecruitingPhase 2
Immunotherapy combinations for advanced kidney cancer
This trial tests a combination of immunotherapy drugs (fianlimab, cemiplimab, and possibly ipilimumab) compared to another immunotherapy combo (ipilimumab + nivolumab) for people with advanced kidney cancer who have not had previous treatment. The goal is to see which combination works better.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06321250RecruitingPhase 1
Study of a new tablet for advanced kidney cancer
This study tests a new tablet (JMKX003948) for people with advanced clear cell kidney cancer. It aims to see if the drug is safe and how well it works.
BeijingAges 18 years+ - NCT07179770RecruitingPhase 1
Belzutifan and imaging in advanced kidney cancer
This trial tests a new drug called belzutifan combined with a special imaging agent (89Zr-DFO-girentuximab) to see how they affect PET scans in people with advanced clear cell kidney cancer. It may help doctors better understand the cancer and guide treatment.
New York, New YorkAges 18 years+ - NCT07645690RecruitingEarly Phase 1
CD70 CAR-T Cell Therapy for Advanced Kidney Cancer
This early-stage trial tests a new type of cell therapy called CD70 CAR-T for advanced kidney cancer (clear cell renal cell carcinoma) that has spread or cannot be surgically removed. The therapy uses cells from your own immune system that are genetically modified to recognize and attack cancer cells.
BeijingAges 18–75 - NCT07615348RecruitingPhase 2
CD70 imaging to guide treatment breaks in advanced kidney cancer
This trial tests whether a special type of imaging scan (CD70-targeted PET/CT) can help doctors safely pause treatment in patients with advanced kidney cancer who respond well to standard immunotherapy and targeted therapy. The goal is to reduce unnecessary treatment while keeping the cancer controlled.
Nanjing, JiangsuAges 18 years+ - NCT05800223RecruitingPhase 3
Armatinib with or without brain radiation for EGFR lung cancer
This study tests whether armatinib alone or combined with focused brain radiation (SRT) can control brain metastases from EGFR-mutated non-small cell lung cancer. It aims to improve outcomes for people with few, mostly low-symptom brain spots.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06428708RecruitingEarly Phase 1
PSMA PET scan for metastatic kidney cancer
This trial uses a special PET scan called PSMA to see if it can better detect kidney cancer that has spread. It may help find tumors that other scans miss.
London, OntarioAges 18 years+ - NCT05176483RecruitingPhase 1
New drug combinations for advanced solid tumors
This trial tests a new drug called zanzalintinib, which may slow or shrink various types of advanced cancer. It is given together with other cancer treatments, and the study is looking at many different cancers including kidney, prostate, bladder, lung, liver, and more.
Phoenix, ArizonaAges 18 years+ - NCT06465069RecruitingPhase 1
Study of a new drug for advanced bladder and other solid tumors
This study tests a new drug (LY4052031) for people with several types of advanced solid tumors, especially bladder cancer. It aims to see if the drug is safe and effective when given alone or after other treatments have stopped working.
Duarte, CaliforniaAges 18 years+ - NCT07226544RecruitingPhase 2
Ivonescimab before surgery for high-risk kidney cancer
This trial tests giving the drug ivonescimab before surgery for patients with high-risk clear cell kidney cancer. The goal is to see if it can help shrink the tumor and improve outcomes.
Duarte, CaliforniaAges 18 years+ - NCT06473961RecruitingPhase 1
GC101 cell therapy for advanced non-small cell lung cancer
This trial tests an experimental cell therapy (GC101) for people with advanced non-small cell lung cancer. It uses your own tumor-fighting immune cells, called TILs, grown in a lab and given back to you. The goal is to see if it can shrink tumors or slow the disease.
ShanghaiAges 18–70 - NCT07594106RecruitingPhase 1/Phase 2
New immunotherapy for advanced prostate or kidney cancer
This trial tests new experimental drugs (REGN15505 and REGN4336) designed to target and attack cancer cells in advanced prostate cancer or kidney cancer. These drugs work by boosting your immune system to recognize and destroy cancer, and may be combined with other approved immunotherapy drugs.
Goodyear, ArizonaAges 18 years+
Hear when a new Renal Cell Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for renal cell cancer metastatic?
- Yes. Clin2 currently lists 605 recruiting renal cell cancer metastatic studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a renal cell cancer metastatic trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a renal cell cancer metastatic trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.